Tuesday, August 02, 2022

Some marijuana smokers seem to have fewer nasal problems
By Amy Norton,
 HealthDay News
August 1, 2022

Research has found that cannabinoids have anti-inflammatory effects, and they might reduce swelling in the mucus membranes -- which, in theory, could help thwart chronic nasal and sinus symptoms. Photo by elsaolofsson/Wikimedia Commons

Could smoking pot somehow help keep sinus problems at bay?

It's possible, suggests a new study that found people who use marijuana may experience fewer bouts of congestion, sneezing and sinus pain than their nonsmoking peers do, though the reasons why remain cloudy.

The study of nearly 2,300 U.S. adults found that while cigarette smokers were often plagued by such symptoms, the same did not hold true for regular marijuana users.

The findings, experts stressed, do not imply that people can chase away a runny nose by lighting up a joint: It's not clear that the drug is actually protective.

It could even be a case of reverse causation, said researcher Dr. Kevin Hur, an otolaryngologist at the University of Southern California's Keck School of Medicine.

That is, people who already have nasal or sinus symptoms might steer clear of marijuana, Hur explained.

At the same time, he and his team speculated, it's possible there are benefits from certain chemicals in the marijuana plant, known collectively as cannabinoids.

Other research has found that cannabinoids have anti-inflammatory effects, and they might reduce swelling in the mucus membranes -- which, in theory, could help thwart chronic nasal and sinus symptoms.

The only way to find out, Hur said, is with further research. Longer-term studies can help sort out the chicken-and-egg question, he noted.

The findings, published in JAMA Otolaryngology-Head & Neck Surgery, are based on 2,269 U.S. adults who took part in a government health study.

Most -- 75% -- said they'd never used marijuana, while 9% regularly used it, and 16% occasionally did. (The survey, conducted in 2013-2014, did not ask people whether they smoked the drug or took it other ways, Hur noted.)

Of regular marijuana users, 45% said they had symptoms like frequent nasal congestion, sneezing or sinus pain, or a dulled sense of smell in the past year. That compared with nearly 65% of people who'd never used marijuana.

Hur's team then looked at other factors, including whether people were cigarette smokers. And it turned out that smokers were twice as likely as nonsmokers to report nasal or sinus symptoms.

In contrast, people who regularly used marijuana were 78% less likely to report those problems, versus never-users -- after factors such as age, race, education and income level were taken into account.

However, there are many variables the study could not assess, according to an otolaryngologist who was not involved in the research.

With nasal and sinus symptoms, exposure to triggers is key, said Dr. Alfred Iloreta, of Mount Sinai's Icahn School of Medicine in New York City.

He explained that chronic rhinitis can have a range of triggers, including air pollution or certain chemicals or other irritants, like dust and mold, at work or at home. Many other people have seasonal symptoms -- better known as hay fever -- that flare when they are exposed to tree, grass or weed pollen.

People who regularly use marijuana may differ from nonusers in at least some of those exposures, Iloreta said.

"I would not want people to take this study as saying you can cure yourself by smoking marijuana," he said.

Smoking the drug, Iloreta noted, would be a particular concern, due to the tiny inhaled particles in the smoke -- which could end up impairing the natural "housekeeping system" in the nose.

Plus, Iloreta said, in someone with asthma, which commonly coexists with nasal symptoms, smoking anything might worsen the lung condition.

"This study does raise the question of whether there's some anti-inflammatory effect of cannabinoids," Iloreta said.

If that's proven to be the case, it could lead to new cannabinoid-based medications for chronic nasal and sinus symptoms, both doctors said.

But until then, they recommended that people with frequent symptoms talk to their doctor about established treatment options, such as medicated nasal sprays.

There are also non-drug remedies, Iloreta pointed out. If people can figure out and avoid their symptom triggers, that goes a long way. Then there's nasal irrigation -- rinsing the nostrils with a salt-water solution, to clear irritants and stimulate that natural housekeeping system in the nose.

"Nasal irrigation, with devices like a neti pot, can work incredibly well," Iloreta said.

More information

The Mayo Clinic has more on chronic nasal/sinus symptoms.

Copyright © 2022 HealthDay. All rights reserved.

Bipartisan senators introduce bill to guarantee abortion rights

A bipartisan group of senators has introduced a bill to codify abortion rights and contraception access after the Supreme Court overturned Roe vs. Wade giving states the right to restrict or ban abortion. File photo by Bonnie Cash/UPI | License Photo

Aug. 1 (UPI) -- A bipartisan group of senators has introduced legislation that would guarantee federal access to abortion, after the Supreme Court overturned Roe vs. Wade, despite a lack of Republican votes to pass the bill.

The Reproductive Freedom For All Act would codify abortion rights and contraception access. It was co-authored by Democratic Sens. Tim Kaine of Virginia and Kyrsten Sinema of Arizona and Republican Sens. Susan Collins of Maine and Lisa Murkowski of Alaska.

"After the Supreme Court gutted the right to choose, I've been working on a bipartisan compromise to restore that right," Kaine said in a tweet. "We just introduced the Reproductive Freedom For All Act -- which would codify Roe v. Wade and enshrine in federal law the right to reproductive freedom."



The new bill is a bipartisan attempt to find a middle ground after Democrats introduced the Women's Health Protection Act, which failed twice in the Senate this year. It would prevent states from enacting laws that put an "undue burden" on access to pre-viability abortions, while also allowing some limits on post-viability abortions except to protect the life or health of the mother. The bill does not define viability.

Seventeen states, including Indiana and West Virginia, have passed abortion ban legislation since Roe vs. Wade was overturned.

"Every American should have autonomy over their own health care decisions, and the Supreme Court's decision in Dobbs has made it imperative for Congress to restore women's reproductive rights," Murkowski said in a tweet. "I'm proud to introduce bipartisan legislation with my colleagues to write into law the protections provided through Roe and Casey as well as affirming access to contraception provided in Griswold and other cases."



The legislation also guarantees federal access to contraception to prevent states from trying to outlaw contraceptives such as Plan B and intrauterine devices.

"For five decades, reproductive health care decisions were centered with the individual," Murkowski said. "We cannot go back in time in limiting personal freedoms for women."
USDA declares salmonella an 'adulterant' in breaded chicken

The U.S. Agriculture Department declared salmonella an adulterant in breaded chicken. File photo by shutterdandan/Shutterstock.com

Aug. 1 (UPI) -- The U.S. Department of Agriculture is taking new steps to protect against salmonella in poultry by declaring the bacteria an adulterant in breaded and stuffed raw chicken products.

The agency's Food Safety and Inspection Service announced Monday breaded raw poultry products will be subject to regulation if they exceed a lower level of salmonella.

FSIS is planning to set the new limit at one colony forming unit of salmonella per gram for breaded raw chicken to significantly reduce the risk of illness. FSIS will also take public comment on whether it should drop the regulatory level down to zero tolerance to make sure contaminated products are never sold.

"Food safety is at the heart of everything FSIS does," said Agriculture Secretary Tom Vilsack. "That mission will guide us as this important first step launches a broader initiative to reduce salmonella illnesses associated with poultry in the U.S."


Since 1998, breaded and stuffed raw chicken products have been associated with as many as 14 outbreaks and approximately 20 illnesses, according to the USDA. Breaded chicken products, such as chicken cordon bleu or chicken Kiev, are usually found in the freezer section.

Many products appear to be cooked, but are only heat-treated to set the batter and breading. FSIS is working to improve product labeling which it says is not always effective at reducing consumer illnesses.

Monday's announcement about regulatory changes for breaded chicken is part of the USDA's larger effort to reduce salmonella illnesses linked to poultry. The USDA announced in October it is targeting a 25% reduction in salmonella poisonings.

Salmonella causes about 1.35 million infections and, according to the Centers for Disease Control and Prevention which blames raw chicken, eggs, fruit and peanut butter for most of the cases.

Last month, a new study found nearly one-third of ground chicken could contain salmonella.

"The USDA has pledged to reduce illness from salmonella contamination for more than a decade, but Consumer Reports' tests show that more progress is clearly needed to protect the public," James Rogers, director of food safety research and testing at Consumer Reports, said last month. "We need tougher action by the USDA to keep salmonella out of our kitchens and off of our plates."

The USDA plans to present its new strategy to reduce salmonella illnesses in poultry in October, with a public meeting scheduled for November.

"Today's announcement is an important moment in U.S. food safety because we are declaring salmonella an adulterant in a raw poultry product," said Sandra Eskin, USDA Deputy Under Secretary for Food Safety. "This is just the beginning of our efforts to improve public health."

82 companies support Harvard, UNC in affirmative action Supreme Court cases


More than 80 corporations on Monday offered their support to Harvard and the University of North Carolina in Supreme Court cases challenging their consideration of race in admissions. 
File Photo by Ken Cedeno/UPI | License Photo

Aug. 1 (UPI) -- A group of 82 corporations on Monday signed onto amicus briefs filed in the Supreme Court defending Harvard and the University of North Carolina's consideration of race in their admissions processes.

The companies, including Apple, Google, Meta Platforms, Starbucks and General Electric signed the briefs arguing that racial and ethnic diversity positively benefits the experience of students at the universities and leads to more diverse workplaces that "enhance business performance.

"Research and experience demonstrate that racial diversity improves decision-making by increasing creativity, communication and accuracy within teams," the companies wrote in one brief.

The briefs came in response to a pair of cases against the universities in the Supreme Court, both filed by Students for Fair Admission, or SFFA, -- a group founded by conservative Edward Blum.

In the Harvard case, SFFA argues that affirmative action rules discriminate against Asian American students while the North Carolina case alleges that Asian-American and White students are discriminated against in favor of Black and Latino applicants.

The group has filed similar lawsuits against affirmative action nationwide.

The companies cited "strong evidence" that supports the notion that university students who study with diverse peers "exhibit enhanced cognitive development" that is needed for a range of skills necessary in the current economy.

"Students of all racial backgrounds benefit from diverse university environments," the brief read. "Building a diverse classroom experience is how to turn out the most informed critical thinkers. Classroom diversity is crucial to producing employable, productive, value-adding citizens in business."

A second amicus brief filed by major science and technology companies argued that a racially diverse workforce helps science, technology, engineering and mathematics, or STEM, companies recruit and retain talent while also contributing to innovations and new technologies that are in line with the needs of their global customer base.

"Companies whose workforces are racially and otherwise diverse will be better equipped to identify and address any number of scientific and technological challenges," the companies wrote. "Tech companies work on unconventional questions that require creative solutions and diverse groups consistently outperform homogenous groups on exactly that type of problem solving."

IBM, Aeris Communications, the Massachusetts Institute of Technology and Stanford University signed a third brief that asserted diversity not only serves to "promote better outcomes for students in STEM" but also "contributes to better science."

"As such, American businesses at the forefront of innovation in STEM depend on the availability of a diverse cross-section of talented graduates from the nation's most rigorous and elite institutions."

The Supreme Court in 2016 ruled 4-3 that "considerable deference is owed to a university in defining those intangible characteristics, like student body diversity, that are central to its identity and educational mission" in a decision authored by Justice Anthony Kennedy.

Kennedy, however, was replaced by Justice Brett Kavanaugh in 2018, and the confirmation of Justice Amy Coney Barrett gave conservatives who have been more critical of affirmative action policies a 6-3 majority on the court.

Justice Samuel Alito in a dissent to the 2016 ruling asserted that affirmative action policies no longer serve the purpose of "helping the disadvantaged.'

"Now we are told that a program that tends to admit poor and disadvantaged minority students is inadequate because it does not work to the advantage of those who are more fortunate," he wrote. "This is affirmative action gone wild."
CRIMINAL CAPITALI$M
Conspiracy website InfoWars parent files for bankruptcy

By Mike Spector
and Dietrich Knauth


Alex Jones of Infowars talks to the media while visiting the U.S. Senate's Dirksen Senate office building as Twitter CEO Jack Dorsey testifies before a Senate Intelligence Committee hearing on Capitol Hill in Washington, U.S., September 5, 2018. Twitter permanently banned Jones and Infowars from its platforms September 6 over his actions seen on Twitter while visiting the building.
REUTERS/Jim Bourg

July 29 (Reuters) - The parent of far-right conspiracy website InfoWars filed for U.S. bankruptcy protection on Friday as the company and its founder Alex Jones face up to $150 million in damages in a trial over longstanding falsehoods he perpetuated about the Sandy Hook elementary school massacre.

The bankruptcy filing by the InfoWars parent, Free Speech Systems LLC, would normally result in the trial and related litigation being halted. But Free Speech plans to ask a bankruptcy judge to allow the trial currently underway in Texas to continue and is seeking an emergency hearing on Monday, according to a court filing.

Nevertheless, Jones and his company could later attempt to use the bankruptcy proceedings, commenced in another Texas court, to limit the size of any damages a jury awards.

A bankruptcy filing by three other InfoWars entities in April proposed $10 million to resolve the litigation, far less than what the Sandy Hook families are seeking. The proposal contemplated legal releases shielding Jones and his company from the lawsuits in exchange for the payment.

The entities that previously declared bankruptcy - InfoW, IW Health and Prison Planet - voluntarily ended their cases in June after the Sandy Hook families dropped them as defendants in the defamation litigation.

Jones was found liable last year in lawsuits Sandy Hook families filed after he falsely claimed that the 2012 school massacre was a hoax. read more

The unusual judgments occurred after Jones defied court orders to turn over documents in the litigation. The cases were then teed up for trials to determine damages, with the first one now underway in an Austin, Texas courtroom.

Jones claimed the shooting, in which 20 children and six school employees were shot dead at the school in Newtown, Connecticut, was fabricated by gun-control advocates and mainstream media. Jones has since acknowledged the shooting happened.

Free Speech Systems believes it is in its best interests to continue the current damages trial because substantial resources have been spent on both sides, and the Sandy Hook plaintiffs would likely fight to keep the trial going despite the bankruptcy filing, W. Marc Schwartz, the company's restructuring advisor, said in a court filing.

The Sandy Hook families had opposed the previous April bankruptcy filing as a "sinister" attempt by Jones to shield his assets from liability. read more

Explaining the current bankruptcy filing, Schwartz said the Sandy Hook litigation resulted in InfoWars being shunned by significant internet, social media and financial institutions. The company's business suffered as a result, he said.

Mark Bankston, a lawyer representing Sandy Hook families, said he looked forward to continuing to put on his case for jurors, which is expected to include testimony as soon as Monday from the parents of one of the children murdered at Sandy Hook Elementary.

"Our clients are pleased that despite the bankruptcy, their trial will continue and that the jury will return a verdict," Bankston told Reuters in a text message. "Now, InfoWars is heading directly for its long awaited, reckoning."

Reporting by Mike Spector, Dietrich Knauth, and Jack Queen; Editing by Chris Reese and Stephen Coates

SPACE RACE 2.0

SpaceX rocket fueled for launch this week to send Korean mission to moon

A SpaceX Falcon 9 rocket is seen at Launch Complex 39A the John F. Kennedy Space Center in Florida on July 14. The Korean mission will be launched into space with a Falcon 9 rocket. Photo by Joe Marino/UPI | License Photo

Aug. 1 (UPI) -- South Korea and SpaceX are fueled and ready to send a spacecraft on a long journey this week that will ultimately take it around the moon.

The Korea Pathfinder Lunar Orbiter is scheduled to launch on Tuesday night from Cape Canaveral in Florida on the back of a SpaceX Falcon 9 rocket.

The KPLO is expected to go into a low-altitude orbit around the moon after it breaks free of the Earth's gravity. South Korean engineers who traveled to the United States for the flight have completed fueling and testing.

"We want to develop critical technology for space exploration as well as for scientific investigation," Eunhyeuk Kim, a KPLO project scientist at the Korean Aerospace Research Institute, said according to Space.org

The launch is scheduled for 7:30 p.m. EDT on Tuesday.

Eventually, the KPLO will go into a polar orbit 62 miles above the lunar surface and perform observations for at least a year.

The key objectives of the project are to measure the magnetic force above the lunar surface and examine lunar resources such as water ice, uranium, helium-3, silicon and aluminum.

The $180 million mission will take a low-energy, fuel-efficient lunar path that's being pioneered by NASA's CAPSTONE spacecraft, which launched last month.

The mission will also create a topographic map that will help scientists on Earth choose future moon landing sites. NASA's Artemis program is aiming to return humans to the lunar surface in 2024.

The KPLO mission is the first step for South Korea's burgeoning lunar exploration program, which plans to put a robotic lander onto the lunar surface by 2030. The country is also planning an asteroid sample-return mission.

RELATEDNASA loses contact with CAPSTONE lunar orbiter after leaving Earth orbit

If it launches this week, the KPLO spacecraft should reach lunar orbit in mid-December.

Dynamic travel restrictions can prevent rapid dispersion of new COVID-19 variants

A study of COVID-19 transmission dynamics in Canada illustrates the role of travel restrictions in buying time to scale up testing, tracing and healthcare interventions

Peer-Reviewed Publication

ELIFE

A study of COVID-19 variant transmission into and across Canada shows that international travel restrictions were a key intervention for reducing or slowing spread, according to a report published today in eLife.

The results suggest that reducing the number of virus importations that can spark domestic outbreaks within a country through dynamic travel bans allows governments more time to prepare for a new variant – by ramping up testing, contact tracing and vaccination programmes.

The COVID-19 pandemic has highlighted the importance of genomic epidemiology – that is, genetic sequencing of SARS-CoV-2 samples from different regions and times – to understand the origin and movement of virus variants internationally, especially variants of concern or interest. These methods have been used widely in the UK, US, Brazil, New Zealand and Europe, and have illustrated the variation in epidemic dynamics between countries that took different public health approaches to containing the virus.

“Large-scale SARS-CoV-2 genomic epidemiology analyses in Canada have so far been limited to a study on the early epidemic within Quebec,” says lead author Angela McLaughlin, Research Assistant at the British Columbia Centre for Excellence in HIV/AIDS, and a PhD candidate in Bioinformatics, University of British Columbia, Canada. “We wanted to elaborate on this research with a national-scale analysis for the first and second COVID-19 waves. We also wanted to evaluate the impact of international travel restrictions in March 2020 on international importations of the virus and to understand why the virus persisted into 2021.”

The team used available sequence data from Canadian COVID-19 cases and data on the prevalence of circulating variants in other countries to estimate the viruses’ geographical origins. From this, they identified more than 2,260 introductions of new variants into Canada, including 680 sublineages – viruses introduced from other countries that went on to circulate within the Canadian population. They also identified 1,582 singletons – ­viruses introduced that did not appear to spread within the Canadian population.

Just as travel restrictions were introduced in April 2020, the importation rate reached its maximum (58.5 sublineages per week), including 31.8 from the US and 31.2 introduced solely into Quebec. Two weeks after travel restrictions took effect, the overall sublineage importation rate had dropped 3.4-fold and within four weeks had dropped 10.3-fold.

Despite these reductions, however, new virus variants continued to be introduced at a low level until August 2020 when there was a small spike in cases leading into the second wave. This suggests that wildtype sublineages introduced in the summer when prevalence and immunity were low contributed the highest proportion of COVID-19 cases in the second wave. In turn, this implies that even a low level of ongoing virus importations of similarly transmissible variants can contribute to viral persistence. By mid-October, travel restrictions were relaxed further, and importation rates rebounded quickly and contributed to the second wave.

By categorising transmission sources as within-province, between province, the US and other international sources, the team could see where the new virus importations were originating. They found that most first-wave virus introductions (January to July 2020) came from the US, followed by Russia, Italy, India, Spain and the UK, and were primarily imported into Quebec and Ontario. In the second wave (August 2020 to end February 2021), the origin of new sublineages was still dominated by the US, with increased relative contributions from India, the UK, Asia, Europe and Africa.

That the US was a large contributor of COVID-19 cases in 2020 was not unanticipated by the authors, given its high COVID-19 prevalence throughout 2020 and the long land border shared between the two countries. Even when international arrivals into Canada declined by 77.8% from 2019 to 2020, the number of truck drivers and crew members (air, ship and train) only declined by 24.8%, and accounted for almost half of all international arrivals after April 2020. Although essential key workers supporting the supply chain, these arrivals may have inadvertently facilitated additional importations from the US – suggesting this is one area where better public health measures, such as contact tracing and rapid testing, could have helped prevent the movement of new variants.

“These analyses shed light on the natural epidemiological history of SARS-CoV-2 in the context of public health interventions and show how sublineage-based genomic surveillance can be used to identify gaps in a country’s epidemic response,” concludes senior author Jeffrey Joy, Research Scientist at the British Columbia Centre for Excellence in HIV/AIDS and Assistant Professor at the Department of Medicine, University of British Columbia. “Broad and longstanding restrictions against non-essential international travel is not necessarily an advisable policy in light of economic impacts. However, our analysis suggests that swift and stringent travel bans towards localities harbouring a high frequency of a new variant of concern, or an outbreak of an entirely new virus, not yet identified domestically, should be seriously considered to reduce the probability of seeding multiple, simultaneous outbreaks and overwhelming healthcare systems.”

##

Media contacts

Emily Packer, Media Relations Manager

eLife

e.packer@elifesciences.org

+44 (0)1223 855373

Edmond Chu, Communications Coordinator

British Columbia Centre for Excellence in HIV/AIDS

+1 (236) 885-4617

echu@bccfe.ca

About eLife

eLife transforms research communication to create a future where a diverse, global community of scientists and researchers produces open and trusted results for the benefit of all. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared. From the research we publish, to the tools we build, to the people we work with, we’ve earned a reputation for quality, integrity and the flexibility to bring about real change. eLife receives financial support and strategic guidance from the Howard Hughes Medical InstituteKnut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.

To read the latest Epidemiology and Global Health research published in eLife, visit https://elifesciences.org/subjects/epidemiology-global-health.

And for the latest in Evolutionary Biology, see https://elifesciences.org/subjects/evolutionary-biology.

About the British Columbia Centre for Excellence in HIV/AIDS

The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada’s largest HIV/AIDS research, treatment and education facility – nationally and internationally recognised as an innovative world leader in combating HIV/AIDS and related diseases. The made-in-BC Treatment as Prevention® strategy (TasP®), pioneered by BC-CfE and supported by UNAIDS since 2011, inspired the ambitious global target for HIV treatment – known as the 90-90-90 Target – to end AIDS as a pandemic by 2030. The BC-CfE is applying TasP® to therapeutic areas beyond HIV/AIDS, including viral hepatitis and addiction, to promote Targeted Disease Elimination® as a means to contribute to healthcare sustainability. The BC-CfE works in close collaboration with key stakeholders, including government, health authorities, healthcare providers, academics, and the community to decrease the health burden of HIV/AIDS, hepatitis C and addictions across Canada and around the world.

SILVER LINING

The health risks of COVID-19 spurred more smokers to quit

New UC San Diego Rady School of Management study is first to track smoking behavior at the individual level during the pandemic

Peer-Reviewed Publication

UNIVERSITY OF CALIFORNIA - SAN DIEGO

Sally Sadoff 

IMAGE: SALLY SADOFF, THE RAFAEL AND MARINA PASTOR CHANCELLOR’S RADY SCHOOL OF MANAGEMENT ENDOWED FACULTY FELLOWSHIP AND ASSOCIATE PROFESSOR OF ECONOMICS AND STRATEGY. view more 

CREDIT: UC SAN DIEGO'S RADY SCHOOL OF MANAGEMENT

Being a smoker makes it more likely for a person to have severe COVID-19 symptoms, require hospitalization or die, which may explain a sharp decrease in smoking behavior among the Danish population during the pandemic, according to new research.

The study from the University of California San Diego’s Rady School of Management. reveals that cigarette purchases among regular smokers decreased by about 20-30% and quitting rates increased by about 10 percentage points from March 2020 to January of 2021. Regular smokers not only purchased cigarettes less frequently, they also cut down on the quantity.

“The pandemic led to reductions in physical activity, increases in stress and declines in mental well-being, all factors commonly associated with triggering higher tobacco use; however, we find evidence of sustained decreases in smoking, which could be a bright spot in the pandemic,” said Sally Sadoff, corresponding author of the study and associate professor of economics and strategy at the Rady School of Management. “The health risks associated with COVID-19 and smoking may help some smokers overcome a key barrier to quitting – that the enjoyment of smoking is felt in the present and health costs are usually felt in the future.”

The paper published in the journal Communications Medicine, shows that declines in smoking were sustained for at least the first year of the pandemic and quitting rates lasted at least six months. These findings suggests COVID-19 may lead to a persistent decline in smoking.

In Denmark, about 17% of the population smokes and in the U.S., about 12.5% percent of the population are smokers.

“Though we cannot make an apples-to-apples comparison to the U.S. due to data limitations, we suspect there was a decline in smoking in this country and others during the same time period,” Sadoff said.

This study is the first to utilize cigarette sales data for both smokers and non-smokers during the pandemic, rather than survey information. The data in the study were made available through Spenderlog, an app that allows users to track their spending on groceries.

Sadoff and co-authors analyzed the grocery purchasing data of 4,042 Danish residents who use the Spenderlog app. The sample is largely representative of the Danish population in terms of age, ethnicity, socioeconomic status and education level.

The researchers find that weekly cigarette purchase rates declined by 24% and average quantities declined by 12% between March 2020 and the end of that year.

However, the data also reveals that social smoking had a slight increase during this same time.

“Contrary to some assumptions, social distancing was not reason there was a drop in smoking because our data reveals that regular smokers, those more likely to smoke alone and those at the highest health risk from smoking, had the strongest reaction to the threat of COVID-19,” Sadoff said.

She continued, “If the decline in smoking we document persists, not only could it help decrease the risks from COVID-19 as new variants emerge, but also have meaningful, longer-term benefits on population health and life expectancy beyond the pandemic.”

The paper “Sustained decline in tobacco purchasing in Denmark during the COVID-19 pandemic” was co-authored by Toke R. Fosgaard of the University of Copenhagen and Alice Pizzo of the Copenhagen Business School.

Long COVID patient registry could support long-term monitoring and service improvements

Peer-Reviewed Publication

SAGE

Recommendations for a voluntary Long COVID patient registry or similar mechanism to monitor the condition in Wales over the long-term offer could support service improvement and offer insight for other future patient registries and health policy decisions, according to the authors of a paper published today by the Journal of the Royal Society of Medicine.

The recommendations were developed by leading independent think tank for health and care, the Bevan Commission. Recommendations include improving healthcare quality by involving both patients and healthcare professionals in the design of a registry and, to promote equity of access, allowing patients to join the registry through self-referral.

The prevalence of Long COVID across the UK remains highly uncertain, but modelling suggests a significant increase. Therefore, managing the long-term consequences in the population will remain a major challenge for health and care services during the next stage of the pandemic.

Baroness Ilora Finlay, Co-Vice Chair of the Bevan Commission and one of the paper’s authors, said: “Despite the uncertainties of Long COVID, the need for long-term monitoring is essential to support research, service improvement and patient engagement. Our recommendations for establishing a Long COVID Registry for Wales, or similar mechanism, provide valuable insight to inform both health policy decisions and patient registries in alternative contexts.”

The Bevan Commission’s other recommendations include the consolidation of digital infrastructures to realise the full potential of a registry, developing a registry with the dual purpose of research and service improvement, and adopting the concept of prudent healthcare, an approach underpinning the work of the Bevan Commission that considers how to collaborate with others, make effective use of the available resources and ensure high quality and consistent care.

Why breast-fed premature infants have a healthier gut than formula-fed ones

A probiotic bacteria strain in preemies seems to protect and strengthen the gut

Peer-Reviewed Publication

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE

Human breastmilk has long been considered “liquid gold” among clinicians treating premature infants in a newborn intensive care unit (NICU). Breastmilk-fed “preemies” are healthier, on average, than those fed formula. Why is that true, however, has remained a mystery.

New research from the University of Maryland School of Medicine’s (UMSOM) Institute for Genome Sciences (IGS), published online in the journal mBio in June found it is not just the content of breastmilk that makes the difference. It is also the way the babies digest it.

The research, led by Bing Ma, PhD, Assistant Professor of Microbiology and Immunology at UMSOM and a researcher at IGS, discovered a strain of the Bifidobacterium breve bacteria or B. breve in the gut of breastfed babies who received higher volumes of breastmilk than their counterparts. Those preemies had better nutrient absorption because they developed an intact intestinal wall, one week after birth. B. breve was much less prevalent in both formula-fed babies and breastfed babies with “leaky gut.” Babies with leaky gut do not develop a barrier to protect against bacteria and digested food from getting into the bloodstream. For the first time, the team also found that the way B. breve metabolizes breastmilk keeps breastfed babies healthier and allows them to gain weight by strengthening their underdeveloped intestinal barrier.

An immature or “leaky” gut can lead to necrotizing enterocolitis (NEC), which is the third leading cause of newborn death in United States and worldwide. In fact, NEC impacts up to 10 percent of premature babies with a devasting mortality rate as high as 50 percent.

“Our discovery could lead to promising and practical clinical interventions to strengthen the babies’ gut and, therefore, increase survival rates of the most vulnerable preemies,” said Dr. Ma.

Bifidobacterium in the gut or microbiome has long been known to have health benefits. It includes a diverse set of strains that have very different properties. Some strains are only found in adults; some are mostly in adolescence. One strain, Bifidobacterium infantis, has been seen predominantly in full-term infants.

The researchers followed 113 premature babies who were born between 24 and 32 weeks’ gestation. This study found Bifidobacterium breve (B. breve) only in preemies who had improved gut barrier function within one week after birth. Dr. Ma and her colleagues discovered that Bifidobacterium breve is genetically equipped to digest nutrients within the cell membrane rather than the more typical external digestion process in which bacteria secrete digestive enzymes onto nutrients to break them down.

At the most basic level, the gut microbiome in these breastfed preemies with more B. breve metabolizes carbohydrates differently than it does formula. The researchers say they hypothesize that this process of metabolism then strengthens and matures the intestinal barrier faster, protecting fragile newborns from disease.

“We now know that it is not the breastmilk alone that helps preemies develop their intestinal barrier faster,” Dr. Ma said. “We will need to find the best way to prophylactically administer B. breve early in life, rather than rely on transmission from breastmilk or even the mother’s gut or vaginal microbiota during the birthing process. This is especially critical in formula-fed preemies.”

Dr. Ma said that more studies are needed to determine if the B. breve originated in the breastmilk, gut, mother’s vagina, or even environment.

E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, University of Maryland, Baltimore, the John Z. and Akiko K. Bowers Distinguished Professor, and Dean at  UMSOM said, “This research can have a far-reaching impact globally. It could ultimately save thousands of premature babies from permanent disability or death associated with an immature and permeable intestine that allows deadly bacteria in.”

Authors from the Institute for Genome Sciences include Dr. Ma; Michael France, PhD, Post-Doc Fellow; Elias McComb, BS, Research Technician; Lindsay Rutt, MS, Laboratory Research Manager; Pawal Gajer, PhD, Research Associate, Microbiology and Immunology; Li Fu, BS, Laboratory Research Specialist; Hongqiu Yang, PhD, Microbiome Service Laboratory; Mike Humphrys, MS, Microbiome Service Laboratory Director; Luke J. Tallon, BA, Executive Scientific Director, Maryland Genomics; Lisa Sadzewicz, PhD, Executive Director, Maryland Genomics Administration; and Jacques Ravel, PhD, Professor of Microbiology and Immunology, Associate Director, Genomics, and Interim Director, IGS.

Authors from other departments within the University of Maryland School of Medicine include Sripriya Sundararajan, MBBS, MD, Associate Professor of Pediatrics and Neonatal Director of OB-MFM Relations; Gita Nadimpalli, MD, PhD, MPH, Graduate Research Assistant; Jose M. Lemme-Dumit, PhD, Post-Doc Fellow, Pediatrics; Elise Janofsky, Pediatrics; Lisa S. Roskes, MD, Pediatrics; Marcela F. Pasetti, PhD, Professor of Pediatrics, Microbiology and Immunology; and Rose M. Viscardi, MD, Professor Emeritus of Pediatrics and Medicine.

This study was supported in part by a Gerber Foundation 2018 award (project identifier 6361), the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grant number R21DK123674), and the Institute for Clinical and Translational Research (ICTR) at the University of Maryland Accelerated Translational Incubator Pilot (ATIP) award.

The authors have no conflict of interest.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding.  As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies.  In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools.  The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the Institute for Genome Sciences: The Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine has revolutionized genomic discoveries in medicine, agriculture, environmental science, and biodefense since its founding in 2007. IGS investigators research areas of genomics and the microbiome to better understand health and disease, including treatments, cures, and prevention. IGS investigators also lead the development of the new field of microbial forensics. IGS is a leading center for major biological initiatives currently underway including the NIH-funded Human Microbiome Project (HMP) and the NIAID-sponsored Genomic Sequencing Center for Infectious Diseases (GSCID). Follow us on Twitter @GenomeScience.